The document discusses implementing personalized healthcare through measuring biomarkers. It notes that while many biomarkers have been discovered, few are validated and applied in diagnostic tests. There is also a gap in translating biomarkers into point-of-care applications. The document advocates for open innovation networks to help validate biomarkers across multiple centers and standardize clinical applications. Ultimately, the focus of personalized healthcare should be on the patient by providing individualized follow-up based on their molecular and clinical measurements.
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2013-04-23 Top Institute Pharma Spring meeting, UtrechtAlain van Gool
Companion diagnostics use biomarkers as diagnostic tools to identify patients who will respond well to specific drug therapies. The presentation discusses the increasing use of companion diagnostics in oncology drug development and clinical trials. It provides examples of biomarkers used to identify patients with melanoma who will benefit from BRAF inhibitor drugs. While some biomarkers like BRAFV600E mutations are useful targets, tumor heterogeneity poses a challenge for companion diagnostics. The presentation calls for improving the pipeline for validating biomarkers and developing them into clinical diagnostic tests.
Alain van Gool presented on biomarkers in personalized healthcare. He discussed how personalized medicine is shifting to personalized healthcare with a systems view that considers multiple factors. Exponential technologies will transform healthcare in the coming years through digital medicine, self-diagnosis, artificial intelligence, and big data. However, gaps remain in translating biomarker discoveries into clinical applications and demonstrating added value. Open innovation is needed to accelerate biomarker development through multi-center validation studies.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
The reality of moving towards precision medicineElia Stupka
How do we move towards precision medicine? How can we deliver on the big data in health promise? Who will be the enablers and players? Pharma, Big Tech, or newcomers?
2019 06-19 Dutch association for clinical chemistry and laboratory medicine -...Alain van Gool
Sharing my views on how X-omics biomarker analyses through next gen sequencing and mass spectrometry will change the landscape of diagnostics and clinical chemistry in the near future.
2013-04-23 Top Institute Pharma Spring meeting, UtrechtAlain van Gool
Companion diagnostics use biomarkers as diagnostic tools to identify patients who will respond well to specific drug therapies. The presentation discusses the increasing use of companion diagnostics in oncology drug development and clinical trials. It provides examples of biomarkers used to identify patients with melanoma who will benefit from BRAF inhibitor drugs. While some biomarkers like BRAFV600E mutations are useful targets, tumor heterogeneity poses a challenge for companion diagnostics. The presentation calls for improving the pipeline for validating biomarkers and developing them into clinical diagnostic tests.
Alain van Gool presented on biomarkers in personalized healthcare. He discussed how personalized medicine is shifting to personalized healthcare with a systems view that considers multiple factors. Exponential technologies will transform healthcare in the coming years through digital medicine, self-diagnosis, artificial intelligence, and big data. However, gaps remain in translating biomarker discoveries into clinical applications and demonstrating added value. Open innovation is needed to accelerate biomarker development through multi-center validation studies.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
The reality of moving towards precision medicineElia Stupka
How do we move towards precision medicine? How can we deliver on the big data in health promise? Who will be the enablers and players? Pharma, Big Tech, or newcomers?
Big data and health sciences: Machine learning in chronic illness by Huiyu DengData Con LA
Abstract:- Big data has become the new hot topic in recent years. It promotes the understanding of the exploit of data and directs the decision guidance in many sectors. The health science field is also shaped by the innovative idea of big data application. Our study group from the department of preventive medicine of the Keck school of medicine of the University of Southern California aims to build a big data architecture that combines and analyzes data of people from difference sources and provide health related assessments back to them. Specifically, ecological momentary assessments (EMAs), electronic medical records (EMRs), and real-time air quality monitor data of children with pre-existing asthma diagnosis are collected and fed into the machine learning models. Asthma exacerbation alert is generated and delivered back to the children before it happens. The machine learning model was tested and built in a similar study. The study population consists of children from a cohort of the prospective, population-based Children's Health Study followed from 2003-2012 in 13 Southern California communities. Potential risk factors were grouped into five broad categories: sociodemographic factors, indoor/home exposures, traffic/air pollution exposures, symptoms/medication use, and asthma/allergy status. The outcome of interest, assessed via annual questionnaire, was the presence of bronchitic symptoms over the prior 12 months. A gradient boosting model (GBM) was trained on data consisting of one observation per participant in a random study year, for a randomly selected half of the study participants. The model was validated using hold-out test data obtained in two complementary approaches: (within-participant) a random (later) year in the same participants and (across-participant) a random year in participants not included in the training data. The predictive ability of risk factor groupings was evaluated using the area under receiver operating characteristic curve (AUC) and accuracy. The predictive ability of individual risk factors was evaluated using the relative variable importance. Graphical visualization of the predictor-outcome relationship was displayed using partial dependency plots. Interaction effects were identified using the H-statistic. Gradient boosting model offers a novel approach to better understand predictive factors for chronic upper respiratory illness such as bronchitic symptoms.
The document summarizes a study that evaluated methods for selecting pregnant or postpartum women with suspected pulmonary embolism (PE) for diagnostic imaging. The study aimed to estimate the accuracy, effectiveness and cost-effectiveness of using clinical features, decision rules and biomarkers to identify which patients need imaging. The study developed a diagnostic model to analyze the performance of these selection methods and assess their ability to safely reduce imaging while maintaining appropriate patient care.
The aim of this review is to summarize the current research studies on dissolvable brain implant consisting of pressure and temperature sensors that can monitor traumatic brain injury and Parkinson’s disease.Full articles with each line detailing available @pharmacyhighlights.com
Thank You for referencing this work, if you find it useful!
Citation of a related scientific paper:
Manea, V., & Wac, K. (2020). Co-Calibrating Physical and Psychological Outcomes and Consumer Wearable Activity Outcomes in Older Adults: An Evaluation of the coQoL Method. Journal of Personalized Medicine, 10(4), 203.
The talk details:
Igor Matias, “Co-calibrating Physical and Psychological Outcomes and Consumer Wearable Activity Outcomes in Older Adults: An Evaluation of the coQoL Method”, Society for Ambulatory Assessment Conference 2021, July 2021.
Video: https://youtu.be/Ht9n2AlIjDs
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
Swiss association Gigaherz will celebrate the 15th anniversary of its existence. On this occasion Gigaherz is organizing Jubiläums-Generalversammlung taking place in Thalvil (near Zurich) on March 7, 2015. These are slides of presentation by Dariusz Leszczynski, the keynote speaker at this meeting, discussing the validity of the currently available science on cell phone radiation and health, in context of the currently ongoing WHO and ICNIRP preparation of the Environmental Health Criteria (presentation will be available afterwards on BRHP).
The document discusses using wearables and sensors in clinical trials. It notes opportunities like more realistic outcomes measures through continuous passive data collection. However, there are also challenges like concerns about device accuracy and privacy. Ensuring data standards and addressing issues around algorithms, privacy and FDA approval will be important for leveraging consumer devices in clinical trials.
This document summarizes Herbalife's nutrition products and business opportunity. It begins by highlighting statistics showing rising consumer spending on health, fitness and body image. It then discusses poor dietary habits as a driver of obesity rates. The document promotes Herbalife's meal replacement shakes and other products as providing balanced nutrition. It outlines Herbalife's global presence and growth since 1980. Testimonials are shared of members losing significant weight using Herbalife products. The business opportunity is described as a way for members to help others achieve results and earn income. In summary, the document promotes Herbalife's products and business by emphasizing health and weight loss trends, balanced nutrition, and income potential.
A empresa de tecnologia anunciou um novo smartphone com câmera aprimorada, maior tela e bateria de longa duração. O dispositivo também possui processador mais rápido e armazenamento expansível. O novo modelo será lançado em outubro por um preço inicial de US$799.
The document proposes a magazine called "Evolution of DBZ" targeted at Dragon Ball Z fans. The core audience would be any gender interested in Dragon Ball Z willing to spend £1 on the magazine. A secondary audience would include those interested in learning about anime or seeing Dragon Ball Z as an interest. The front cover would appeal to audiences with colorful images of a DBZ character and the creator portraying a fighting pose, along with a martial arts symbol relating to DBZ and the creator. The main article would provide bright, colorful information about the newest Dragon Ball franchise iteration in an engaging style. Advertisements would use big fonts to promote related anime games and cinema systems. The total proposed annual budget is £240,000,
3 ways fragmented clinical communication is compromising patient carePatientSafe Solutions
1. Patient care is delayed due to inefficient systems and workflows
2. Multi-device digital communication complicates critical context
3. Unmanaged use of personal smartphones jeopardizes PHI security
This document discusses bridging research and healthcare by translating biomarkers into patient treatment. It provides background on Prof. Alain van Gool and his roles at TNO, Radboud University Nijmegen Medical Centre, and Radboud University Nijmegen. It outlines the need for biomarkers in pharmaceutical drug development and personalized healthcare to address the biomarker innovation gap and develop personal profiles for conditions like oncology and diabetes. Progress may be made through open innovation networks.
A empresa de tecnologia anunciou um novo smartphone com câmera avançada, bateria de longa duração e processador rápido para competir no mercado. O dispositivo custará menos do que os principais concorrentes e estará disponível em várias cores para atender a diferentes gostos. A empresa espera que o novo aparelho ajude a aumentar sua participação no mercado de smartphones.
+ Overview of MOBILE EVOLUTION AND DEVELOPMENT OF THE INTERNET.
+ MOBILE INTERNET: TRENDS AND GROWTH
+ BENEFITS OF THE MOBILE INTERNET
+ CHALLENGES OF THE MOBILE INTERNET
+ SOLUTIONS
Using Cisco pxGrid for Security Platform Integration: a deep diveCisco DevNet
A session in the DevNet Zone at Cisco Live, Berlin. This session will cover: Functional and architectural basics of Cisco Platform Exchange Grid (pxGrid), the new publish/subscribe/query contextual information exchange framework for creating integration between DevNet Zone partner platforms and Cisco security products; Integration use-cases such as utilizing pxGrid for executing threat response actions on the network and using identity, endpoint device and user access privilege context to enhance our DevNet Zone partners analytics, forensics and reporting; First-hand developer perspective from DevNet Zone partner ID/IP who used pxGrid to integrate Ping Identity and Cisco Identity Services Engine.
2015 05-20 Radboudumc REshape breakfast meeting Alain van GoolAlain van Gool
This document discusses biomarkers in personalized healthcare and moving beyond targeted medicine. It provides an overview of the speaker's background and experience in academia, pharmaceutical industry, and medical school related to biomarkers, omics technologies, and personalized healthcare. It then discusses the exponential developments in biomarker technologies, the need for a systems biology view in personalized healthcare, and translation challenges in bridging the gap between biomarkers and personalized interventions for patients.
Consumer barriers to mobile internet adoption in AsiaTuan Anh Nguyen
This research examines why more than 2 billion people in the region can access the internet but are holding back from doing so.
This includes data from six markets in the region: China, India, Indonesia, Philippines, Thailand and Vietnam with approximately 1,000 people in each country
This document discusses using psychology and photography to create a personal brand identity. It includes sections on owning your identity, posing to diminish weaknesses, and having an assertive interpersonal style. Unconscious beliefs, values, and behaviors are explored as shaping personal brands at deep levels. The document provides guidance on next steps for developing a brand identity through self-reflection.
The document analyzes millions of tweets to identify the biggest mistakes in marketing and advertising, which it calls the "7 deadly sins". The sins are identified as marketing saturation, constant interruption, poor creative quality, poor targeting, deceptive claims, insensitivity and selfishness, and excessive repetition. For each sin, example tweets expressing frustration are provided, as well as recommendations for marketers to avoid the sin such as focusing on quality over quantity and avoiding disruption of the user experience.
Big data and health sciences: Machine learning in chronic illness by Huiyu DengData Con LA
Abstract:- Big data has become the new hot topic in recent years. It promotes the understanding of the exploit of data and directs the decision guidance in many sectors. The health science field is also shaped by the innovative idea of big data application. Our study group from the department of preventive medicine of the Keck school of medicine of the University of Southern California aims to build a big data architecture that combines and analyzes data of people from difference sources and provide health related assessments back to them. Specifically, ecological momentary assessments (EMAs), electronic medical records (EMRs), and real-time air quality monitor data of children with pre-existing asthma diagnosis are collected and fed into the machine learning models. Asthma exacerbation alert is generated and delivered back to the children before it happens. The machine learning model was tested and built in a similar study. The study population consists of children from a cohort of the prospective, population-based Children's Health Study followed from 2003-2012 in 13 Southern California communities. Potential risk factors were grouped into five broad categories: sociodemographic factors, indoor/home exposures, traffic/air pollution exposures, symptoms/medication use, and asthma/allergy status. The outcome of interest, assessed via annual questionnaire, was the presence of bronchitic symptoms over the prior 12 months. A gradient boosting model (GBM) was trained on data consisting of one observation per participant in a random study year, for a randomly selected half of the study participants. The model was validated using hold-out test data obtained in two complementary approaches: (within-participant) a random (later) year in the same participants and (across-participant) a random year in participants not included in the training data. The predictive ability of risk factor groupings was evaluated using the area under receiver operating characteristic curve (AUC) and accuracy. The predictive ability of individual risk factors was evaluated using the relative variable importance. Graphical visualization of the predictor-outcome relationship was displayed using partial dependency plots. Interaction effects were identified using the H-statistic. Gradient boosting model offers a novel approach to better understand predictive factors for chronic upper respiratory illness such as bronchitic symptoms.
The document summarizes a study that evaluated methods for selecting pregnant or postpartum women with suspected pulmonary embolism (PE) for diagnostic imaging. The study aimed to estimate the accuracy, effectiveness and cost-effectiveness of using clinical features, decision rules and biomarkers to identify which patients need imaging. The study developed a diagnostic model to analyze the performance of these selection methods and assess their ability to safely reduce imaging while maintaining appropriate patient care.
The aim of this review is to summarize the current research studies on dissolvable brain implant consisting of pressure and temperature sensors that can monitor traumatic brain injury and Parkinson’s disease.Full articles with each line detailing available @pharmacyhighlights.com
Thank You for referencing this work, if you find it useful!
Citation of a related scientific paper:
Manea, V., & Wac, K. (2020). Co-Calibrating Physical and Psychological Outcomes and Consumer Wearable Activity Outcomes in Older Adults: An Evaluation of the coQoL Method. Journal of Personalized Medicine, 10(4), 203.
The talk details:
Igor Matias, “Co-calibrating Physical and Psychological Outcomes and Consumer Wearable Activity Outcomes in Older Adults: An Evaluation of the coQoL Method”, Society for Ambulatory Assessment Conference 2021, July 2021.
Video: https://youtu.be/Ht9n2AlIjDs
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
Swiss association Gigaherz will celebrate the 15th anniversary of its existence. On this occasion Gigaherz is organizing Jubiläums-Generalversammlung taking place in Thalvil (near Zurich) on March 7, 2015. These are slides of presentation by Dariusz Leszczynski, the keynote speaker at this meeting, discussing the validity of the currently available science on cell phone radiation and health, in context of the currently ongoing WHO and ICNIRP preparation of the Environmental Health Criteria (presentation will be available afterwards on BRHP).
The document discusses using wearables and sensors in clinical trials. It notes opportunities like more realistic outcomes measures through continuous passive data collection. However, there are also challenges like concerns about device accuracy and privacy. Ensuring data standards and addressing issues around algorithms, privacy and FDA approval will be important for leveraging consumer devices in clinical trials.
This document summarizes Herbalife's nutrition products and business opportunity. It begins by highlighting statistics showing rising consumer spending on health, fitness and body image. It then discusses poor dietary habits as a driver of obesity rates. The document promotes Herbalife's meal replacement shakes and other products as providing balanced nutrition. It outlines Herbalife's global presence and growth since 1980. Testimonials are shared of members losing significant weight using Herbalife products. The business opportunity is described as a way for members to help others achieve results and earn income. In summary, the document promotes Herbalife's products and business by emphasizing health and weight loss trends, balanced nutrition, and income potential.
A empresa de tecnologia anunciou um novo smartphone com câmera aprimorada, maior tela e bateria de longa duração. O dispositivo também possui processador mais rápido e armazenamento expansível. O novo modelo será lançado em outubro por um preço inicial de US$799.
The document proposes a magazine called "Evolution of DBZ" targeted at Dragon Ball Z fans. The core audience would be any gender interested in Dragon Ball Z willing to spend £1 on the magazine. A secondary audience would include those interested in learning about anime or seeing Dragon Ball Z as an interest. The front cover would appeal to audiences with colorful images of a DBZ character and the creator portraying a fighting pose, along with a martial arts symbol relating to DBZ and the creator. The main article would provide bright, colorful information about the newest Dragon Ball franchise iteration in an engaging style. Advertisements would use big fonts to promote related anime games and cinema systems. The total proposed annual budget is £240,000,
3 ways fragmented clinical communication is compromising patient carePatientSafe Solutions
1. Patient care is delayed due to inefficient systems and workflows
2. Multi-device digital communication complicates critical context
3. Unmanaged use of personal smartphones jeopardizes PHI security
This document discusses bridging research and healthcare by translating biomarkers into patient treatment. It provides background on Prof. Alain van Gool and his roles at TNO, Radboud University Nijmegen Medical Centre, and Radboud University Nijmegen. It outlines the need for biomarkers in pharmaceutical drug development and personalized healthcare to address the biomarker innovation gap and develop personal profiles for conditions like oncology and diabetes. Progress may be made through open innovation networks.
A empresa de tecnologia anunciou um novo smartphone com câmera avançada, bateria de longa duração e processador rápido para competir no mercado. O dispositivo custará menos do que os principais concorrentes e estará disponível em várias cores para atender a diferentes gostos. A empresa espera que o novo aparelho ajude a aumentar sua participação no mercado de smartphones.
+ Overview of MOBILE EVOLUTION AND DEVELOPMENT OF THE INTERNET.
+ MOBILE INTERNET: TRENDS AND GROWTH
+ BENEFITS OF THE MOBILE INTERNET
+ CHALLENGES OF THE MOBILE INTERNET
+ SOLUTIONS
Using Cisco pxGrid for Security Platform Integration: a deep diveCisco DevNet
A session in the DevNet Zone at Cisco Live, Berlin. This session will cover: Functional and architectural basics of Cisco Platform Exchange Grid (pxGrid), the new publish/subscribe/query contextual information exchange framework for creating integration between DevNet Zone partner platforms and Cisco security products; Integration use-cases such as utilizing pxGrid for executing threat response actions on the network and using identity, endpoint device and user access privilege context to enhance our DevNet Zone partners analytics, forensics and reporting; First-hand developer perspective from DevNet Zone partner ID/IP who used pxGrid to integrate Ping Identity and Cisco Identity Services Engine.
2015 05-20 Radboudumc REshape breakfast meeting Alain van GoolAlain van Gool
This document discusses biomarkers in personalized healthcare and moving beyond targeted medicine. It provides an overview of the speaker's background and experience in academia, pharmaceutical industry, and medical school related to biomarkers, omics technologies, and personalized healthcare. It then discusses the exponential developments in biomarker technologies, the need for a systems biology view in personalized healthcare, and translation challenges in bridging the gap between biomarkers and personalized interventions for patients.
Consumer barriers to mobile internet adoption in AsiaTuan Anh Nguyen
This research examines why more than 2 billion people in the region can access the internet but are holding back from doing so.
This includes data from six markets in the region: China, India, Indonesia, Philippines, Thailand and Vietnam with approximately 1,000 people in each country
This document discusses using psychology and photography to create a personal brand identity. It includes sections on owning your identity, posing to diminish weaknesses, and having an assertive interpersonal style. Unconscious beliefs, values, and behaviors are explored as shaping personal brands at deep levels. The document provides guidance on next steps for developing a brand identity through self-reflection.
The document analyzes millions of tweets to identify the biggest mistakes in marketing and advertising, which it calls the "7 deadly sins". The sins are identified as marketing saturation, constant interruption, poor creative quality, poor targeting, deceptive claims, insensitivity and selfishness, and excessive repetition. For each sin, example tweets expressing frustration are provided, as well as recommendations for marketers to avoid the sin such as focusing on quality over quantity and avoiding disruption of the user experience.
This document discusses data protection and risk mitigation under South Africa's Protection of Personal Information Act (POPI). It addresses key issues like identifying personal data and systems impacted by POPI, information security safeguards, records management policies, digital content and app ownership, and considerations for protecting young people's data. The document provides recommendations like conducting a POPI audit, appointing an information officer, and establishing policies regarding privacy, security, and intellectual property.
The document proposes a magazine called "Evolution of DBZ" targeted at Dragon Ball Z fans. The core audience would be any gender interested in Dragon Ball Z willing to spend £1 on the magazine. A secondary audience would include those interested in learning about anime or seeing Dragon Ball Z as an interest. The front cover would appeal to audiences with colorful images of a DBZ character and the creator portraying a fighting pose, along with a martial arts symbol relating to DBZ and the creator. The main article would provide bright, colorful information about the newest Dragon Ball franchise iteration in an engaging style. Advertisements would use big fonts to promote related anime games and cinema systems. The total proposed annual budget is £240,000,
The social media landscape is evolving quickly too; Facebook still dominates - and continues to grow - but the remaining spots in the top 5 of our latest platform rankings are held by mobile messenger services.....
Instructions on how to get matched to your right financial advisor. This presentation demonstrates the steps that you will take in order to get matched to the right advisor.
2015 12-09 Opening Radboud Translational Medicine, Nijmegen, Alain van GoolAlain van Gool
Keynote opening lecture at the grand opening of our new cyclotron facility, embedded in Radboud Translational Medicine and part of our Radboudumc Technology Centers. See http://www.radboudtranslationalmedicine.nl/nl/ for details.
2016 05-24 Kick-off The Danish Biomarker Network, Copenhagen, Alain van GoolAlain van Gool
Keynote lecture given at the kick-off of The Danish Biomarker Network in Copenhagen for a great audience of enthousiastic patients, biotech/pharma developers and ICT experts.
2016-02-18 Innovation for Health 2016 conference, Rotterdam Alain van GoolAlain van Gool
Lecture on personalized healthcare in a great session at the Innovation for Health 2016 conference, discussing opportunities and challenges with 800 scientists, enterpreneurs and care professionals.
2020 08-28 SensUs Event 2020 keynote, Eindhoven, Alain van GoolAlain van Gool
Closing keynote for international students participating in the SensUs Event 2020, where they designed and created a novel sensor for drug level monitoring in epilepsy treatment. Lecture outlined innovations in biomarkers in personalized health(care).
2018 12-07 Danone-Nutricia Precision Nutrition Forum, Utrecht, Alain van GoolAlain van Gool
1. The document discusses innovations in personalized health and healthcare using various omics technologies and big data. It highlights developments in genomics, metabolomics, glycomics, and proteomics that enable personalized diagnosis and therapy.
2. Several examples are provided of how multi-omics approaches combined with whole exome sequencing can identify new disease mechanisms and biomarkers for precision medicine in genetic disorders.
3. The development of systems approaches that integrate multi-level omics data, environment, and lifestyle factors is needed to create personalized data-driven tools to monitor health and provide customized recommendations.
2022-09-08 ECPM Digital Biomarkers and AI, Basel, Alain van Gool.pdfAlain van Gool
Lecture for 150 pharma professionals to outline the potentials and things-to-do with digital biomarkers, as part of a ECPM training on digitization and AI in drug development.
2014 02-24 Oxford Global biomarker congress, ManchesterAlain van Gool
This document summarizes a presentation given by Alain van Gool on biomarkers in a changing world. It discusses the shift from personalized medicine to personalized healthcare, which takes a more holistic systems view of an individual. It also notes disruptive technologies that can accelerate biomarker development and the need to translate biomarkers into useful tools. Throughout, it provides examples of challenges like tumor heterogeneity and factors beyond genetics that influence disease and response to treatment.
Pharma-Nutrition: a pharma perspective. View how the pharmaceutical drug development model can and should be combined with the nutrition field to optimally implement personalized healthcare.
Great evening with the Rotary Oss where I got the opportunity to discuss current and future prospects in personalized healthcare with a good group of interested people.
2016 11-15 Lygature partnership meetup, Utrecht, Alain van GoolAlain van Gool
Contribution to the opening of the Joint Innovation Mile in the Beatrix building in Utrecht, home of the offices of Lygature, HealthRI, BBMRI-NL and others to follow.
2014 07-08 Selectbio Biomarkers 2014, CambridgeAlain van Gool
The document discusses biomarkers in personalized healthcare from discovery to clinical diagnostics, providing an overview of the speaker's experience in academia, pharmaceutical industry, and applied research focusing on biomarkers and omics technologies. It also describes the Radboud University Medical Center's focus on personalized healthcare through its technology centers and biomarker research on conditions like metabolic syndrome. The discussion emphasizes how biomarkers are evolving from diagnosis to tools that enable personalized and participatory healthcare approaches.
2016 09-12 Europe Biobanking Week, Vienna, Alain van GoolAlain van Gool
Opening keynote of the Europe Biobanking Week, outlining reasons why we should join forces in validation and development of biomarker in personalized medicinand health.
2013-10-02 Dutch CC symposium on Personalized Healthcare, EdeAlain van Gool
This document summarizes a presentation about companion diagnostics and personalized healthcare. It discusses how companion diagnostics can identify the right drug, dose, and timing for a patient by using biomarkers to characterize biological systems and diseases. It provides examples of companion diagnostic use in oncology and challenges in biomarker development and validation. Overall it advocates applying well-characterized therapies guided by biomarkers to better understand and treat disease in a personalized manner.
2020 09-07 European Center Pharmaceutical Medicine course Biomarkers, Basel, ...Alain van Gool
Tutorial lecture on biomarkers for pharmaceutical industry R&D professionals, outlining status, potential and challenges of biomarkers in pharma, clinic and society.
2017 03-07 World Economic Forum - Dutch topsector Life Science Health, The Ha...Alain van Gool
The document discusses the Netherlands' approach to personalized medicine and health research. It outlines key principles of precision medicine including targeting the right drug, dose, and time for each patient. It also describes the Netherlands' national infrastructure supporting personalized medicine research through biobanks, clinical records, and other data sources. Mass spectrometry is highlighted as a technique enabling discovery of new glycoprotein biomarkers from human plasma samples.
2015 06-02 Steering group 'Personalized Medicine: eligible or not'Alain van Gool
Update for the steering group of the project "Personalized Medcine: eligble or not?", aiming to define whether and how to implement pharmacogenetic screening by first line care practitioners.
2023-11-14 Biomarkers Europe 2023, Berlin, Alain van Gool.pdfAlain van Gool
Lecture at the Biomarkers Europe 2023 conference for an audience of pharma scientists and omics/data solution providers. I outlined several initiatives of potential interest and discussed development of our sensitive personalized clinical biomarker test for minimal residual disease monitoring in multiple myeloma.
2023-11-09 HealthRI Biobanking day_Amsterdam_Alain van Gool.pdfAlain van Gool
Examples of lessons learned in Omics-based biomarker studies from myself and colleagues in X-omics and EATRIS, for an audience of biobankers, researchers and diagnostic/clinical chemistry experts.
2023-04-20 EATRIS-Plus Summerschool, Lisbon, Alain van GoolAlain van Gool
Closing keynote lecture at the EATRIS-Plus summerschool on personalised medicine, outlining developments, opportunities, challenges and recommendations to do next in this exciting era of personalised medicine.
2022-11-23 DTL Future of data-driven life sciences, Utrecht, Alain van Gool.pdfAlain van Gool
A pitch on directions to improve experimental reproducibility, illustrated by examples of past experiences. I made the plee to move from 'Proudly invented here' to 'Proudly copyied from', to re-use each other's eperiences in successes and failures.
2022-10-12 The future of population health_Alain van Gool.pdfAlain van Gool
1) Exponential developments in omics technologies like genomics, proteomics, and metabolomics are driving more personalized approaches to healthcare.
2) Mass spectrometry methods have been developed to sensitively detect minimal residual disease in multiple myeloma patients from plasma samples, allowing for dynamic monitoring and earlier detection of relapse compared to traditional methods.
3) Large-scale multi-omics studies incorporating data from various sources can provide a more holistic view of health and disease at both the individual and population levels, supporting personalized prevention and treatment approaches.
2022-04-14 EuroMedLab, Munich, Alain van GoolAlain van Gool
Keynote lecture at the EuroMedLab 2021 providing an audience of clinical chemists and laboratory medicine scientists with advancements of multi-omics applications in personalized healthcare, and challenges that we need to solve as translational scientists.
2021 12-10 Amalia Science Day, Nijmegen, Alain van GoolAlain van Gool
This document discusses the use of omics technologies like genomics, proteomics, and glycoproteomics in pediatric healthcare. Specifically, it describes a study that used glycoproteomics to analyze blood samples from children with febrile illness to distinguish between viral and bacterial infections. The analysis identified glycoprotein biomarkers that could accurately classify 70-80% of samples as viral or bacterial. Integrating multiple omics data through machine learning approaches may provide a more comprehensive understanding of diseases and lead to personalized diagnosis and treatment.
2021 06-14 EATRIS-Plus summer school, Alain van GoolAlain van Gool
Introductory lecture for the 100 participant summer school of the EATRIS-Plus project, outlining personalized medicine, biomarker and multi-omics strategies and use cases.
2021 03-25 11th World Clinical Biomarkers & Companion Diagnostics, Alain van ...Alain van Gool
Closing keynote of a 3-day conference on clinical biomarkers and companion diagnostics, organised by Hanson Wade, outlining the power of omics approaches in healthcare and translation of inovations to impact.
2020 02-10 European Center Pharmaceutical Medicine course - biomarkers, Basel...Alain van Gool
This document discusses biomarkers and personalized healthcare. It begins with an overview of biomarkers in the pharmaceutical industry and how they are used from drug discovery through clinical trials. It then discusses biomarkers in academic research and healthcare, and how emerging digital biomarkers could enable personalized health monitoring. The presentation identifies some translational innovation gaps, and concludes with an outlook on how biomarkers and multi-omics approaches will continue to advance personalized diagnosis and therapies.
2019 10-14 2nd Int Congress on Precision Medicine, Munich, Alain van GoolAlain van Gool
Opening lecture at the 2nd International Congress on Precision Medicine in Munich, outlining progress in omics-based biomarkers for rare diseases, biomarker innovation gaps and multi-partner initiatives to bridge those gaps to applications. Also reviewed the highlights of our recently published Handbook of Biomarkers and Precision Medicine.
2019 09-23 COST CliniMARK summerschool, Spetses, Alain van GoolAlain van Gool
Opening lecture of the COST CliniMARK summer school 'Approaches for Biomarker Discovery and Validation'. Extensive introduction in biomarker approached used in pharmaceutical industry, academic research and clinical care, and society, combined with review of biomarker innovation gaps and outlook.
Lecture describing workflows and case studies from the Translational Metabolic Laboratory @Radboudumc how to translate x-omics biomarker signatures to clinical implementation. I also highlighted new developments to join forces in the Netherlands X-omics Initiative, United for Metabolic Disease and events/book launches in the next months.
2019 03-14 Health Valley Event 2019, Nijmegen, Alain van GoolAlain van Gool
Lecture on innovations in personalized healthcare using an integrated X-omics approach towards personalized diagnostics, as part of the regional ambitious TopFit program.
2019 02-21 Oxford Global 14th Biomarker Congress, Manchester, Alain van GoolAlain van Gool
1. Professor Alain van Gool presented on using clinical x-omics to drive personalized healthcare.
2. He described case studies where combining different omic approaches like genomics, metabolomics, and glycomics led to novel disease mechanisms and therapies for rare genetic diseases.
3. Van Gool advocated for increased collaboration and standardization of omic technologies to advance precision medicine and bring clinical multi-omics to higher diagnostic and therapeutic levels.
2019 01-19 Retina symposium 2019, Amsterdam, Alain van Gool
2015 07-03 Nanonext NL Alain van Gool, Amsterdam
1. Implementing Personalized Health(care):
the need to bridge fields
Professor of Personalized Healthcare
Head Radboud Center for Proteomics, Glycomics
and Metabolomics
Coordinator Radboud Technology Centers
Head Biomarkers in Personalized Healthcare
Prof Alain van Gool
NanoNextNL Medicine Theme Day
3 July 2015, Amsterdam
2. My mixed perspectives in personalized health(care)
8 years academia (NL, UK)
(molecular mechanisms of disease)
13 years pharma (EU, USA, Asia)
(biomarkers, Omics)
3,5 years med school (NL)
(personalized healthcare, Omics, biomarkers)
3,5 years applied research institute (NL, EU)
(biomarkers, personalized health, nutrition)
A person / citizen / family man
(adventures in EU, USA, Asia)
1991-1996 1996-1998 2009-2012
1999-2007 2007-2009 2009-2011
2011-now
2011-now
2
2 Alain van Gool, NanoNext.NL, 3 July 2015
4. Key aspects of personalized health(care)
‘Let’s stay healthy. If not, how to get healthy?’
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
4 Alain van Gool, NanoNext.NL, 3 July 2015
6. Source: Chakma Journal of Young Investigators. Vol 16, 2009.
Principle of Personalized/Precision/Targeted Medicine
6
6 Alain van Gool, NanoNext.NL, 3 July 2015
8. 8 Alain van Gool, NanoNext.NL, 3 July 2015
Optimal Personalized / Precision / Targeted Medicine
9. EC DG for Research and Innovation
Alain van Gool
Brussels, 11 Sept 2012
System biology
approach needed in:
Diagnosis
Prognosis
Treatment
Monitoring
People are complex biological systems
10. Personalized health(care), more than pathways only
Source: Barabási 2007 NEJM 357; 4}
• People are different
• Different networks and influences
• Different risk factors
• Different preferences
10
10 Alain van Gool, NanoNext.NL, 3 July 2015
12. A changing world: Personalized Medicine@ USA
“The term "personalized medicine" is
often described as providing "the
right patient with the right drug at
the right dose at the right time."
More broadly, "personalized
medicine" may be thought of as the
tailoring of medical treatment to the
individual characteristics, needs, and
preferences of a patient during all
stages of care, including prevention,
diagnosis, treatment, and follow-up.”
(FDA, October 2013)
12
12 Alain van Gool, NanoNext.NL, 3 July 2015
13. A changing world: Personalized Medicine @Europe
European Science Foundation
30 Nov 2012
Innovative Medicine Initiative 2
8 July 2013
EC Horizon2020
10 Dec 2013
13
13 Alain van Gool, NanoNext.NL, 3 July 2015
14. Personalized Healthcare @ Radboudumc
People are different Stratification by multilevel diagnosis
+Patient’s preference of treatment
Exchange experiences in
care communities Select personalized therapy
Population
Man
Molecule
14
14 Alain van Gool, NanoNext.NL, 3 July 2015
15. Societal goal of personalized health(care)
15
Source: prof Jan Kremer
15 Alain van Gool, NanoNext.NL, 3 July 2015
17. Key aspects of personalized health(care)
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
17 Alain van Gool, NanoNext.NL, 3 July 2015
18. Exponential technologies
“The only constant is change,
and the rate of change is
increasing”
We are at the knee
of the exponential curve
18 Alain van Gool, NanoNext.NL, 3 July 2015
21. Exponential developments in biomarker technologies
• Next generation sequencing
• DNA, RNA
• Risk analysis and therapy selection
• Mass spectrometry
• Proteins, metabolites
• Monitoring of disease and treatment effects
• Imaging
• Non invasive images, real time
• Spatial view of intact organs and organisms
21 Alain van Gool, NanoNext.NL, 3 July 2015
23. Mass spectrometry
• Example: Glycoproteomics in plasma
• Detection of ~12.000 unique deconvoluted monoisotopic masses
per single analysis (> 50% are glycopeptides)
500
1000
1500
2000
m/z
5 10 15 20 25 30 35 40 Time [min]
Proof of principle study:
Monique van Scherpenzeel, Dirk Lefeber, Hans Wessels, Alain van Gool
Translational Metabolic Laboratory, Radboudumc, unpublished data
23 Alain van Gool, NanoNext.NL, 3 July 2015
24. Imaging
Slide courtesy of Maroeska Rovers, Peter Friedl, Otto Boerman, Radboudumc
Example: Image-guided surgery:
• Use (auto)fluorescence to highlight tumor cells
• Specific removal of tumor tissue
• Extend to other imaging modalities in operation room (eg MRI)
24 Alain van Gool, NanoNext.NL, 3 July 2015
29. • DIY sequence your genome and/or your microbiome
genome
• at a provider, at a pharmacy, at home
• Take your genome to the doctor
• Have a personalized healthcare advice
DIY sequencing
29 Alain van Gool, NanoNext.NL, 3 July 2015
30. 30
• Measure your brain waves (EEG)
• Recognize conditions for maximal
concentration or relaxation.
• Use device to train.
DIY brainwave monitoring
30 Alain van Gool, NanoNext.NL, 3 July 2015
31. DIY blood biomarker analysis
• Measure key biomarkers in one drop of blood at few $ per test panel
• Download data to your smartphone to monitor your own trend
31 Alain van Gool, NanoNext.NL, 3 July 2015
38. But …
Knowledge and Innovation gap:
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
38 Alain van Gool, NanoNext.NL, 3 July 2015
39. Biomarker innovation gaps
39
Discovery Clinical
validation/confirmation
Diagnostic
test
Number of
biomarkers
Gap 1
Gap 2
Gap 3
1. Imbalance between biomarker discovery, validation and application
2. Many more biomarkers discovered than available as diagnostic test
3. Limited translation to point-of-care devices
39 Alain van Gool, NanoNext.NL, 3 July 2015
40. Biomarker innovation gaps: some numbers
40
5 biomarkers/
working day
1 biomarker/
1-3 years
1 biomarker/
3-10 years
?
Eg Biomarkers in time: Prostate cancer
May 2011: n= 2,231 biomarkers
Nov 2012: n= 6,562 biomarkers
Oct 2013: n= 8,358 biomarkers
Nov 2014: n= 10,350 biomarkers
Discovery Clinical
validation/confirmation
Diagnostic
test
Number of
biomarkers
Gap 1
Gap 2
Gap 3
40 Alain van Gool, NanoNext.NL, 3 July 2015
41. Way forward: Open Innovation Networks
Shared R&D in biomarkers:
1. Assay development of (diagnostic) biomarkers
2. Clinical biomarker validation (quantification/confirmation, multicenter)
Leading to standardised clinical applications
(Source model: TNO’s Holst Center)
41 Alain van Gool, NanoNext.NL, 3 July 2015
42. Interdisciplinary biomarker validation
Standardisation, harmonisation,
knowledge sharing in:
1. Assay development
2. Clinical validation
Biomarker Development Center
Open
Innovation
Network !
Roadmap Molecular Diagnostics
PPP Grant 4.3M Euro
42
42 Alain van Gool, NanoNext.NL, 3 July 2015
44. Good example of multi-center biomarker validation
44 Alain van Gool, NanoNext.NL, 3 July 2015
45. But …
Knowledge and Innovation gap:
1. What to measure?
2. How much can it change?
3. What should be the follow-up for me?
45 Alain van Gool, NanoNext.NL, 3 July 2015
46. Most important in Personalized Healthcare:
Focus on the end user: the patient / citizen
46
46 Alain van Gool, NanoNext.NL, 3 July 2015
47. The route to Personalized Health(care)
47 Alain van Gool, NanoNext.NL, 3 July 2015
48. Analogy: TOMTOM
GPS to a location
Utrecht
Amsterdam
Utrecht
Amsterdam
Route 1 Route 2
= Default Traffic jam near Utrecht Alternative route
48 Alain van Gool, NanoNext.NL, 3 July 2015
49. Personalized Health(care) model
GPS to health
Risk
Health
Route 1 Route 2
= Default
First signs of
disease risk
Alternative route
Now
Risk
Health
Now
Health
49 Alain van Gool, NanoNext.NL, 3 July 2015
50. Personalized Health(care) model
Analogies:
• Technology enabled
• Personal choice to actively monitor or not
• Success through participation of user
• Monitoring should be on the background;
only alert when risk
• Commercial competition of tool builders to
standard of market leader(s)
• Implementation as standard in society
GPS to health
50 Alain van Gool, NanoNext.NL, 3 July 2015
52. Translation is key in Personalized Healthcare !
Personal profile data
Knowledge
Understanding
Decision
Action
52
52 Alain van Gool, NanoNext.NL, 3 July 2015
53. System biologist’s world
53
β-cell Pathology
gluc Risk factor
{Source: Ben van Ommen, TNO}
therapy
53 Alain van Gool, NanoNext.NL, 3 July 2015
54. Translation is key in Personalized Healthcare !
“I’m afraid you’re
suffering from an
increased IL-1β and
an aberrant miR843
expression”
Adapted from:
54
?
54 Alain van Gool, NanoNext.NL, 3 July 2015
55. Translation is key in Personalized Healthcare !
Select personalized therapy
Treatment options
Successrates
Example from Prostate cancer patient guide
55 Alain van Gool, NanoNext.NL, 3 July 2015
56. Translation is key in Personalized Healthcare !
Treatment options
Pro’sCon’s
Select personalized therapy
56 Alain van Gool, NanoNext.NL, 3 July 2015
57. Explore personalized interventions by Pharma-Nutrition
Shared Innovation Programs through public-private consortia
Higher efficacy / less side effects
57
57 Alain van Gool, NanoNext.NL, 3 July 2015
58. Interact – Educate – speak each other language
58
58 Alain van Gool, NanoNext.NL, 3 July 2015
59. Interact – Educate – speak each other language
59
59 Alain van Gool, NanoNext.NL, 3 July 2015
60. Acknowledgements
Ron Wevers
Jolein Gloerich
Hans Wessels
Monique Scherpenzeel
Dirk Lefeber
Leo Kluijtmans
Lucien Engelen
Paul Smits
Maroeska Rovers
Nathalie Bovy
Bas Bloem
and many others
www.radboudumc.nl/personalizedhealthcare
www.radboudumc.nl/research/technologycenters
www.radboudresearchfacilities.nl
alain.vangool@tno.nl
alain.vangool@radboudumc.nl
www.linkedIn.com
www.slideshare.net/alainvangool
Many collaborators
Jan van der Greef
Ben van Ommen
Bas Kremer
Lars Verschuren
Ivana Bobeldijk
Marjan van Erk
Carina de Jongh
Peter van Dijken
Robert Kleemann
Suzan Wopereis
and many others
60
And funders
CarTarDis
60 Alain van Gool, NanoNext.NL, 3 July 2015